The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burger, R.
Right arrow Articles by Naser, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burger, R.
Right arrow Articles by Naser, W.

The Journal of Immunology, Vol 141, Issue 2 553-558, Copyright © 1988 by American Association of Immunologists

ARTICLES

The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinant with diagnostic potential

R Burger, G Zilow, A Bader, A Friedlein and W Naser
Institute for Immunology, University of Heidelberg, Federal Republic of Germany.

Activation of the C component C3 results in generation of the anaphylatoxin C3a. The C3a polypeptide chain consists of 77 amino acids. The active site of this potent mediator, which also has immunoregulatory function resides in its C terminus. This report demonstrates that the C terminus of C3a (C3a-desArg) exposed by proteolytic cleavage from C3 represents a neoantigenic determinant. Two mAb specific for this epitope were obtained after immunization with the synthetic octapeptide (OP) Arg-Ala-Ser-His-Leu-Gly-Leu-Ala [C3a(69-76)] coupled to the carrier keyhole limpet hemocyanin (KLH). These anti- C3a(69-76) antibodies (H453 and H454) reacted in an ELISA system with C3a and KLH-OP but not with C3 or with KLH alone. Free OP efficiently blocked binding of the antibodies to C3a, whereas binding of another anti-C3a mAb (H13) remained unaffected. In immunoblotting analysis, the anti-C3a(69-76) mAb reacted with purified C3a but failed to react with the denatured, noncleaved C3. A novel quantitative C3a-ELISA was established with the anti-C3a(69-76) mAb. It had a sensitivity in the nanogram range (1 to 5 ng/ml). The C3a determination was not impaired by the presence of high concentrations of C3. Therefore, C3 removal was not required in contrast to the previously described C3a assays. This C3a ELISA might facilitate clinical C3a quantitation, e.g., in samples from patients with adult respiratory distress syndrome. In these patients, C3a determination in the early phase of the disease is of diagnostic relevance and has prognostic value.


This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
J. Saleh, L. K. M. Summers, K. Cianflone, B. A. Fielding, A. D. Sniderman, and K. N. Frayn
Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period
J. Lipid Res., April 1, 1998; 39(4): 884 - 891.
[Abstract] [Full Text]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
J. Sonntag, M. H Wagner, E. Strauss, and M. Obladen
Complement and contact activation in term neonates after fetal acidosis
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 1998; 78(2): 125F - 128.
[Abstract] [Full Text]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
R. L. Korn, C. A. Fisher, E. R. Livingston, N. Stenach, S. J. Fishman, V. Jeevanandam, and V. P. Addonizio
THE EFFECTS OF CARMEDA BIOACTIVE SURFACE ON HUMAN BLOOD COMPONENTS DURING SIMULATED EXTRACORPOREAL CIRCULATION
J. Thorac. Cardiovasc. Surg., May 1, 1996; 111(5): 1073 - 1084.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.